Novel peptide compound

Abstract

Disclosed is a novel compound represented by the formula (1) below or a pharmaceutically acceptable salt thereof. Also disclosed is a use of such a compound or salt in cancer immunotherapy. (1) [In the formula, X represents a tyrosine residue or a methionine residue; Y and Z respectively represent a single bond or the like; R<1> represents a hydrogen atom or the like; R<2> represents a hydroxyl group or the like; R<3> represents a hydrogen atom, an alkyl group, an amino group or the like; R<4> represents a hydrogen atom, an alkyl group, a carboxy group or the like; m represents 1 or 2; and n represents an integer of 0-2. In this connection, when n is 0, R<3> represents a hydrogen atom or an alkyl group.]

Description

technical field [0001] The present invention relates to cancer vaccine therapy, and in particular to novel peptide compounds useful as drugs in cancer immunotherapy. Specifically, the present invention relates to derivatives of cancer antigen peptides derived from WT1, which have in vivo CTL-inducing activity and are useful as cancer vaccines. technical background [0002] Cell-mediated immunity, especially cytotoxic T cells (hereinafter referred to as "CTL"), play an important role in rejecting cancer cells or virus-infected cells in vivo. CTLs can recognize the gap between antigenic peptides derived from cancer antigen proteins ("cancer antigen peptides") on cancer cells and MHC (major histocompatibility complex) class I antigens (called "HLA" antigens in humans) complex, and attacks and kills the cell. Cancer antigen peptides capable of binding MHC class I molecules are generally known to be peptides having 8-12 amino acid residues produced by intracellular processing ...

AI Technical Summary

Problems solved by technology

This spontaneous oxidation has been reported to reduce the binding affinity of the peptide to MHC class I molecules and the cognitive response of T cell receptors to the peptide (see Non-Patent Documents 1 and 2)

Images